Beyond Survival: Arthur's Lung Cancer Treatment
“The medical technology in China was years ahead of what I was offered locally. But it was the human care that made me feel safe.”
— Arthur P., United Kingdom
Condition
Non-Small Cell Lung Cancer
An Unexpected Diagnosis
Arthur, a 56-year-old architect from London, was diagnosed with stage IIIA non-small cell lung cancer during a routine health screening. His NHS treatment plan involved conventional chemotherapy and radiation, with a guarded prognosis.
Seeking Better Options
Through his own research, Arthur discovered that Chinese hospitals were performing a combination of immunotherapy and minimally invasive thoracic surgery that wasn't yet standard in the UK. MediPath China arranged a remote second opinion with a thoracic oncology team.
Treatment in China
Arthur's treatment plan combined neoadjuvant immunotherapy followed by video-assisted thoracoscopic surgery (VATS), a minimally invasive approach that preserved healthy lung tissue.
Results
Arthur's surgery successfully removed the tumor with clear margins. Post-operative pathology showed a complete pathological response to the immunotherapy — meaning no viable cancer cells remained in the resected tissue. Two years later, Arthur remains cancer-free.
Your story could begin here
Request a confidential case review to explore your treatment options in China.
Request Case Review